<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tempus Ai, Inc. Class A Common Stock — News on 6ix</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock</link>
<description>Latest news and press releases for Tempus Ai, Inc. Class A Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tempus-ai-inc-class-a-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-usc-announce-strategic-collaboration-to-accelerate-ai-driven-precision-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-usc-announce-strategic-collaboration-to-accelerate-ai-driven-precision-medicine</guid>
<pubDate>Thu, 23 Apr 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, April 23, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a multi-faceted collaboration aimed at transforming patient care and accelerating research through the power of data and AI. This collaboration is designed to transform care delivery across more than 1.5 million annual patient visits to the USC Norris Comprehensive Cancer Center, the</description>
</item>
<item>
<title>Tempus to Report First Quarter 2026 Financial Results on May 5</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-report-first-quarter-2026-financial-results-on-may-5</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-report-first-quarter-2026-financial-results-on-may-5</guid>
<pubDate>Tue, 21 Apr 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, April 21, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026.</description>
</item>
<item>
<title>Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-predicta-biosciences-announce-collaboration-to-expand-life-sciences-access-to-ultrasensitive-whole-genome-sequencing-assay-for-hematologic-malignancies-and-mrd-monitoring</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-predicta-biosciences-announce-collaboration-to-expand-life-sciences-access-to-ultrasensitive-whole-genome-sequencing-assay-for-hematologic-malignancies-and-mrd-monitoring</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta</description>
</item>
<item>
<title>Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-31-abstracts-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-31-abstracts-for-presentation-at-the-american-association-for-cancer-research-annual-meeting-2026</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the</description>
</item>
<item>
<title>Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-launches-automated-active-follow-up-service-to-support-guideline-concordant-care</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the</description>
</item>
<item>
<title>Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-strategic-collaboration-with-gilead-to-advance-oncology-randd-through-rwe</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-strategic-collaboration-with-gilead-to-advance-oncology-randd-through-rwe</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an</description>
</item>
<item>
<title>Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-medtronic-announce-alert-trial-results-showing-ai-driven-ehr-notifications-improve-treatment-for-significant-valvular-heart-disease</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-medtronic-announce-alert-trial-results-showing-ai-driven-ehr-notifications-improve-treatment-for-significant-valvular-heart-disease</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the</description>
</item>
<item>
<title>Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-blood-cancer-unitedr-announce-collaboration-to-develop-one-of-the-largest-pediatric-acute-myeloid-leukemia-real-world-data-registries</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-and-blood-cancer-unitedr-announce-collaboration-to-develop-one-of-the-largest-pediatric-acute-myeloid-leukemia-real-world-data-registries</guid>
<pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
<description>CHICAGO, March 17, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer.</description>
</item>
<item>
<title>Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-study-highlighting-the-role-of-advanced-genomic-profiling-features-in-identifying-clinically-actionable-findings</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-study-highlighting-the-role-of-advanced-genomic-profiling-features-in-identifying-clinically-actionable-findings</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the</description>
</item>
<item>
<title>Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-strategic-collaboration-agreement-with-merck-to-accelerate-ai-driven-precision-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-strategic-collaboration-agreement-with-merck-to-accelerate-ai-driven-precision-medicine</guid>
<pubDate>Tue, 03 Mar 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, March 03, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios.</description>
</item>
<item>
<title>Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-participate-in-the-morgan-stanley-technology-media-and-telecom-conference</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-to-participate-in-the-morgan-stanley-technology-media-and-telecom-conference</guid>
<pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, February 26, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST.</description>
</item>
<item>
<title>Tempus Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-reports-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-reports-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care,</description>
</item>
<item>
<title>Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-novel-pan-cancer-133000431</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-novel-pan-cancer-133000431</guid>
<pubDate>Wed, 18 Feb 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, February 18, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays.</description>
</item>
<item>
<title>Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-collaboration-with-median-technologies-to-integrate-ai-powered-lung-cancer-screening-into-the-pixel-platform</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-collaboration-with-median-technologies-to-integrate-ai-powered-lung-cancer-screening-into-the-pixel-platform</guid>
<pubDate>Thu, 12 Feb 2026 05:00:00 GMT</pubDate>
<description>CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a</description>
</item>
<item>
<title>Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-report-fourth-quarter-full-133000992</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-report-fourth-quarter-full-133000992</guid>
<pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, February 10, 2026--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET.</description>
</item>
<item>
<title>Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/ambrys-contributions-to-maves-support-thousands-of-patient-reclassifications-and-expand-to-new-genes</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/ambrys-contributions-to-maves-support-thousands-of-patient-reclassifications-and-expand-to-new-genes</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary</description>
</item>
<item>
<title>Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/ambry-genetics-announces-one-millionth-test-leveraging-rna-to-improve-diagnostic-accuracy-and-yield</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/ambry-genetics-announces-one-millionth-test-leveraging-rna-to-improve-diagnostic-accuracy-and-yield</guid>
<pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
<description>Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry</description>
</item>
<item>
<title>Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-reveals-ai-driven-ips-133000303</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-reveals-ai-driven-ips-133000303</guid>
<pubDate>Tue, 27 Jan 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, January 27, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), and PD-L1.</description>
</item>
<item>
<title>Tempus Announces the Launch of Paige Predict</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-launch-paige-predict-133000058</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-announces-launch-paige-predict-133000058</guid>
<pubDate>Wed, 21 Jan 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, January 21, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence or absence of clinically actionable and relevant biomarkers directly from a single H&E slide, offering</description>
</item>
<item>
<title>Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology</title>
<link>https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-nyu-langone-health-announce-133000446</link>
<guid isPermaLink="true">https://6ix.com/company/tempus-ai-inc-class-a-common-stock/news/tempus-nyu-langone-health-announce-133000446</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>CHICAGO, January 12, 2026--Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health’s Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center, a comprehensive, pan-cancer initiative to more</description>
</item>
</channel>
</rss>